SCHEMBL11370588

SCHEMBL11370588

Cc1cccc(-c2nc3cc(S(=O)(=O)Nc4ccccc4Cl)ccc3[nH]2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.52
KMT2A Q03164 7/20 0.49
MEN1 O00255 6/20 0.49
TP53 P04637 4/20 0.49
LMNA P02545 3/20 0.49
SMN1; SMN2 Q16637 4/20 0.46
TDP1 Q9NUW8 2/20 0.46
ALDH1A1 P00352 1/20 0.46
PKM P14618 1/20 0.46
MAPK1 P28482 1/20 0.46
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46
KDM4E B2RXH2 2/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
TSHR P16473 2/20 0.43
PTK2B Q14289 1/20 0.43
HSD11B1 P28845 1/20 0.41
THRB P10828 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6925674 0.89 MAPT (0.49) MAPTKMT2AMEN1TP53LMNA
SCHEMBL6925491 0.88 GRM4 (0.51) MAPTKMT2AMEN1TP53LMNA
SCHEMBL6925468 0.85 CBFB (0.53) MAPTKMT2AMEN1LMNASMN1; SMN2
SCHEMBL6925493 0.83 MAPT (0.48) MAPTKMT2AMEN1TP53LMNA
SCHEMBL11370367 0.83 MAPT (0.48) MAPTKMT2AMEN1TP53LMNA
SCHEMBL6926045 0.82 MAPT (0.67) MAPTKMT2AMEN1TP53LMNA
SCHEMBL11370441 0.82 MAPT (0.53) MAPTKMT2AMEN1TP53LMNA
SCHEMBL6926521 0.82 MAPT (0.51) MAPTKMT2AMEN1TP53LMNA
SCHEMBL6925864 0.81 MEN1 (0.50) MAPTKMT2AMEN1TP53LMNA
SCHEMBL6925486 0.80 GRM4 (0.51) MAPTKMT2AMEN1TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS GRM4, GRIK4, GRIA4 MAPT 3868/4885KMT2A 1413/4885MEN1 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.